Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Archives of Gynecology and Obstetrics
Erschienen in: Archives of Gynecology and Obstetrics 5/2016

14.09.2016 | Review

The future therapy of endometrial cancer: microRNA’s functionality, capability, and putative clinical application

verfasst von: Matthias B. Stope, Dominique Koensgen, Jörg Weimer, Madeleine Paditz, Martin Burchardt, Dirk Bauerschlag, Alexander Mustea

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Endometrial cancer (EC) therapy is characterized by the heterogeneity of EC subtypes resulting in unclear clinical behavior as well as in unsatisfactory treatment options. The available biomarkers, such as cellular tumor antigen p53 (TP53), phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase (PTEN), and phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) genes alone might not be sufficient, and thus, new predictive and prognostic biomarkers are urgently required. The biomolecule class of microRNA represents a group of endogenously expressed regulatory factors primarily involved in control of pivotal cancer-related mechanisms including cell cycle, proliferation, apoptosis, and metastasis. Here, we review the current state of science regarding microRNA functionality in EC progression.
Literatur
1.
Purdie DM, Green AC (2001) Epidemiology of endometrial cancer. Best Pract Res Clin Obstet Gynaecol 15:341–354CrossRefPubMed
2.
3.
Pitson G, Colgan T, Levin W, Lockwood G, Manchul L, Milosevic M, Murphy J, Fyles A (2002) Stage II endometrial carcinoma: prognostic factors and risk classification in 170 patients. Int J Radiat Oncol Biol Phys 53:862–867CrossRefPubMed
4.
Sehouli J, Koensgen D, Oskay-Ozcelik G, Mustea A (2008) New aspects of adjuvant therapy in endometrial cancer: current standards and future directions. Crit Rev Oncol Hematol 67:204–212CrossRefPubMed
5.
Mustea A, Koensgen D, Belau A, Sehouli J, Lichtenegger W, Schneidewind L, Sommer H, Markmann S, Scharf JP, Ehmke M, Ledwon P, Braicu I, Zygmunt M, Koehler G (2013) Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology). Cancer Chemother Pharmacol 72:975–983CrossRefPubMed
6.
Creasman WT, Kohler MF, Odicino F, Maisonneuve P, Boyle P (2004) Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol 95:593–596CrossRefPubMed
7.
Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, Graham JE (1991) Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 40:55–65CrossRefPubMed
8.
9.
10.
Felix AS, Weissfeld JL, Stone RA, Bowser R, Chivukula M, Edwards RP, Linkov F (2010) Factors associated with type I and type II endometrial cancer. Cancer Causes Control 21:1851–1856CrossRefPubMedPubMedCentral
11.
Schultheis AM, Martelotto LG, DeFilippo MR, Piscuglio S, Ng CK, Hussein YR, Reis-Filho JS, Soslow RA, Weigelt B (2015) TP53 mutational spectrum in endometrioid and serous endometrial cancers. Int J Gynecol Pathol. doi:10.​1097/​PGP.​0000000000000243​ (in press)
12.
Marchio C, De Filippo MR, Ng CK, Piscuoglio S, Soslow RA, Reis-Filho JS, Weigelt B (2015) PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas. Gynecol Oncol 137:321–328CrossRefPubMed
13.
Chang Y, Huang H, Yeh K, Chang J (2016) Genetic alterations in endometrial cancer by targeted next-generation sequencing. Exp Mol Pathol 100:8–12CrossRefPubMed
14.
O’Hara AJ, Bell DW (2012) The genomics and genetics of endometrial cancer. Adv Genom Genet 2012:33–47
15.
Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497:67–73CrossRefPubMed
16.
17.
Jovanovic M, Hengartner MO (2006) miRNAs and apoptosis: RNAs to die for. Oncogene 25:6176–6187CrossRefPubMed
18.
19.
Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, Bar-Eli M, Dinney C (2009) miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 15:5060–5072CrossRefPubMed
20.
Acunzo M, Romano G, Wernicke D, Croce CM (2015) MicroRNA and cancer—a brief overview. Adv Biol Regul 57:1–9CrossRefPubMed
21.
Zhang B, Pan X, Cobb GP, Anderson TA (2007) microRNAs as oncogenes and tumor suppressors. Dev Biol 302:1–12CrossRefPubMed
22.
Zhou J, Song T, Gong S, Zhong M, Su G (2010) microRNA regulation of the expression of the estrogen receptor in endometrial cancer. Mol Med Rep 3:387–392PubMed
23.
Pan Q, Chegini N (2008) MicroRNA signature and regulatory functions in the endometrium during normal and disease states. Semin Reprod Med 26:479–493CrossRefPubMedPubMedCentral
24.
Pan Q, Luo X, Toloubeydokhti T, Chegini N (2007) The expression profile of micro-RNA in endometrium and endometriosis and the influence of ovarian steroids on their expression. Mol Hum Reprod 13:797–806CrossRefPubMed
25.
Cohn DE, Fabbri M, Valeri N, Alder H, Ivanov I, Liu C, Croce CM, Resnick KE (2010) Comprehensive miRNA profiling of surgically staged endometrial cancer. Am J Obstet Gynecol 202:656.e1–656.e8CrossRef
26.
Wu W, Lin Z, Zhuang Z, Liang X (2009) Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. Eur J Cancer Prev 18:50–55CrossRefPubMed
27.
Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Wei Z, Kamath S, Chen D, Dressman H, Lancaster JM (2008) MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecol Oncol 110:206–215CrossRefPubMed
28.
Chung TK, Cheung TH, Huen N, Wong KW, Lo KW, Yim SF, Siu NS, Wong YM, Tsang P, Pang M, Yu M, To K, Mok SC, Wang VW, Li C, Cheung AY, Doran G, Birrer MJ, Smith DI, Wong Y (2009) Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer 124:1358–1365CrossRefPubMed
29.
Torres A, Torres K, Pesci A, Ceccaroni M, Paszkowski T, Cassandrini P, Zamboni G, Maciejewski R (2013) Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients. Int J Cancer 132:1633–1645CrossRefPubMed
30.
Ratner ES, Tuck D, Richter C, Nallur S, Patel RM, Schultz V, Hui P, Schwartz PE, Rutherford TJ, Weidhaas JB (2010) MicroRNA signatures differentiate uterine cancer tumor subtypes. Gynecol Oncol 118:251–257CrossRefPubMedPubMedCentral
31.
Devor EJ, Hovey AM, Goodheart MJ, Ramachandran S, Leslie KK (2011) microRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs. Oncol Rep 26:995–1002PubMedPubMedCentral
32.
33.
Xiong H, Li Q, Liu S, Wang F, Xiong Z, Chen J, Chen H, Yang Y, Tan X, Luo Q, Peng J, Xiao G, Jiang Q (2014) Integrated microRNA and mRNA transcriptome sequencing reveals the potential roles of miRNAs in stage I endometrioid endometrial carcinoma. PLoS One 9:e110163CrossRefPubMedPubMedCentral
34.
Kontomanolis EN, Koukourakis MI (2015) MicroRNA: the potential regulator of endometrial carcinogenesis. MicroRNA 4:18–25CrossRefPubMed
35.
Lu J, Zhang X, Zhang R, Ge Q (2015) MicroRNA heterogeneity in endometrial cancer cell lines revealed by deep sequencing. Oncol Lett 10:3457–3465PubMedPubMedCentral
36.
Canlorbe G, Wang Z, Laas E, Bendifallah S, Castela M, Lefevre M, Chabbert-Buffet N, Darai E, Aractingi S, Mehats C, Ballester M (2016) Identification of microRNA expression profile related to lymph node status in women with early-stage grade 1–2 endometrial cancer. Mod Pathol 29:391–401CrossRefPubMed
37.
Hiroki E, Akahira J, Suzuki F, Nagase S, Ito K, Suzuki T, Sasano H, Yaegashi N (2010) Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci 101:241–249CrossRefPubMed
38.
Banno K, Yanokura M, Iida M, Adachi M, Nakamura K, Nogami Y, Umene K, Masuda K, Kisu I, Nomura H, Kataoka F, Tominaga E, Aoki D (2014) Application of microRNA in diagnosis and treatment of ovarian cancer. Biomed Res Int 2014:232817CrossRefPubMedPubMedCentral
39.
Romero-Perez L, Lopez-Garcia MA, Diaz-Martin J, Biscuola M, Castilla MA, Tafe LJ, Garg K, Oliva E, Matias-Guiu X, Soslow RA, Palacios J (2013) ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma. Mod Pathol 26:1514–1524CrossRefPubMed
40.
Yanokura M, Banno K, Kobayashi Y, Kisu I, Ueki A, Ono A, Masuda K, Nomura H, Hirasawa A, Susumu N, Aoki D (2010) MicroRNA and endometrial cancer: roles of small RNAs in human tumors and clinical applications (review). Oncol Lett 1:935–940PubMedPubMedCentral
41.
Jia W, Wu Y, Zhang Q, Gao G, Zhang C, Xiang Y (2013) Identification of four serum microRNAs from a genome-wide serum microRNA expression profile as potential non-invasive biomarkers for endometrioid endometrial cancer. Oncol Lett 6:261–267PubMedPubMedCentral
42.
He S, Zeng S, Zhou Z, He Z, Zhou S (2015) Hsa-microRNA-181a is a regulator of a number of cancer genes and a biomarker for endometrial carcinoma in patients: a bioinformatic and clinical study and the therapeutic implication. Drug Des Dev Ther 9:1103–1175
43.
Lee TS, Jeon HW, Kim YB, Kim YA, Kim MA, Kang SB (2013) Aberrant microRNA expression in endometrial carcinoma using formalin-fixed paraffin-embedded (FFPE) tissues. PLoS One 8:e81421CrossRefPubMedPubMedCentral
44.
Feng B, Wang R, Chen L (2012) Review of miR-200b and cancer chemosensitivity. Biomed Pharmacother 66:397–402CrossRefPubMed
45.
Banno K, Kisu I, Yanokura M, Masuda K, Kobayashi Y, Ueki A, Tsuji K, Yamagami W, Nomura H, Susumu N, Aoki D (2012) Endometrial cancer and hypermethylation: regulation of DNA and microRNA by epigenetics. Biochem Res Int 2012:738274CrossRefPubMedPubMedCentral
46.
Tsuruta T, Kozaki K, Uesugi A, Furuta M, Hirasawa A, Imoto I, Susumu N, Aoki D, Inazawa J (2011) miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res 71:6450–6462CrossRefPubMed
47.
Huang Y, Liu JC, Deatherage DE, Luo J, Mutch DG, Goodfellow PJ, Miller DS, Huang TH (2009) Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res 69:9038–9046CrossRefPubMedPubMedCentral
48.
Li B, Lu C, Lu W, Yang T, Qu J, Hong X, Wan X (2013) miR-130b is an EMT-related microRNA that targets DICER1 for aggression in endometrial cancer. Med Oncol 30:484CrossRefPubMed
49.
Chen J, Wang Y, McMonechy MK, Anglesio MS, Yang W, Senz J, Maines-Bandiera S, Rosner J, Trigo-Gonzalez G, Grace Cheng SW, Kim J, Matzuk MM, Morin GB, Huntsman DG (2015) Recurrent DICER1 hotspot mutations in endometrial tumours and their impact on microRNA biogenesis. J Pathol 237:215–225CrossRefPubMed
50.
Hiroki E, Suzuki F, Akahira J, Nagase S, Ito K, Sugawara J, Miki Y, Suzuki T, Sasano H, Yaegashi N (2012) MicroRNA-34b functions as a potential tumor suppressor in endometrial serous adenocarcinoma. Int J Cancer 131:E395–E404CrossRefPubMed
51.
Shen Y, Lu L, Xu J, Meng W, Qing Y, Liu Y, Zhang B, Hu H (2013) Bortezomib induces apoptosis of endometrial cancer cells through microRNA-17-5p by targeting p21. Cell Biol Int 37:1114–1121CrossRefPubMed
52.
Yan G, Yu F, Wang B, Zhou H, Ge Q, Su J, Hu Y, Sun H, Ding L (2014) MicroRNA miR-302 inhibits the tumorigenicity of endometrial cancer cells by suppression of Cyclin D1 and CDK1. Cancer Lett 345:39–47CrossRefPubMed
53.
Sun K, Chen Y, Chen S, Liu B, Feng M, Zong Z, Zhao Y (2016) The correlation between microRNA490-3p and TGFα in endometrial carcinoma tumorigenesis and progression. Oncotarget 7:9236–9249PubMedPubMedCentral
54.
Li Q, Qiu X, Li Q, Wang X, Li L, Xu M, Dong M, Xiao Y (2015) MicroRNA-424 may function as a tumor suppressor in endometrial carcinoma cells by targeting E2F7. Oncol Rep 33:2354–2360PubMed
55.
Park Y, Lee J, Choi J, Jeon H, Cho Y, Choi C, Kim T, Lee NW, Kim B, Bae D (2012) The interactions between MicroRNA-200c and BRD7 in endometrial carcinoma. Gynecol Oncol 124:125–133CrossRefPubMed
56.
57.
Guo Y, Liao Y, Jia C, Ren J, Wang J, Li T (2013) MicroRNA-182 promotes tumor cell growth by targeting transcription elongation factor A-like 7 in endometrial carcinoma. Cell Physiol Biochem 32:581–590CrossRefPubMed
58.
Wu Y, Liu S, Xin H, Jiang J, Younglai E, Sun S, Wang H (2011) Up-regulation of microRNA-145 promotes differentiation by repressing OCT4 in human endometrial adenocarcinoma cells. Cancer 117:3989–3998CrossRefPubMed
59.
Xu Y, Tian J, Hao Q, Yin L (2015) MicroRNA-495 downregulates FOXC1 expression to suppress cell growth and migration in endometrial cancer. Tumour Biol 37:239–251CrossRefPubMedPubMedCentral
60.
Konno Y, Dong P, Xiong Y, Suzuki F, Lu J, Cai M, Watari H, Mitamura T, Hosaka M, Hanley Sharon J B, Kudo M, Sakuragi N (2014) MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells. Oncotarget 5:6049–6062CrossRefPubMedPubMedCentral
61.
Gao Y, Liu T, Huang Y (2015) MicroRNA-134 suppresses endometrial cancer stem cells by targeting POGLUT1 and Notch pathway proteins. FEBS Lett 589:207–214CrossRefPubMed
62.
Wu D, Huang H, He C, Wang K (2013) MicroRNA-199a-3p regulates endometrial cancer cell proliferation by targeting mammalian target of rapamycin (mTOR). Int J Gynecol Cancer 23:1191–1197CrossRefPubMed
63.
Zhang H, Wang X, Chen Z, Wang W (2015) MicroRNA-424 suppresses estradiol-induced cell proliferation via targeting GPER in endometrial cancer cells. Cell Mol Biol (Noisy-le-grand) 61:96–101
64.
Chen S, Sun K, Liu B, Zong Z, Zhao Y (2016) MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-α. Mol Cancer 15:11CrossRefPubMedPubMedCentral
65.
Liu B, Sun K, Zong Z, Chen S, Zhao Y (2015) MicroRNA-372 inhibits endometrial carcinoma development by targeting the expression of the Ras homolog gene family member C (RhoC). Oncotarget 7:6649–6664PubMedCentral
66.
Qin X, Yan L, Zhao X, Li C, Fu Y (2012) microRNA-21 overexpression contributes to cell proliferation by targeting PTEN in endometrioid endometrial cancer. Oncol Lett 4:1290–1296PubMedPubMedCentral
67.
Chung TKH, Lau TS, Cheung TH, Yim SF, Lo KWK, Siu NSS, Chan LKY, Yu MY, Kwong J, Doran G, Barroilhet LM, Ng ASW, Wong RRY, Wang VW, Mok SC, Smith DI, Berkowitz RS, Wong YF (2012) Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1. Int J Cancer 130:1036–1045CrossRefPubMed
68.
Dong P, Kaneuchi M, Watari H, Sudo S, Sakuragi N (2014) MicroRNA-106b modulates epithelial-mesenchymal transition by targeting TWIST1 in invasive endometrial cancer cell lines. Mol Carcinog 53:349–359CrossRefPubMed
69.
Dong P, Kaneuchi M, Watari H, Hamada J, Sudo S, Ju J, Sakuragi N (2011) MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer 10:99CrossRefPubMedPubMedCentral
70.
Mitamura T, Watari H, Wang L, Kanno H, Kitagawa M, Hassan MK, Kimura T, Tanino M, Nishihara H, Tanaka S, Sakuragi N (2014) microRNA 31 functions as an endometrial cancer oncogene by suppressing Hippo tumor suppressor pathway. Mol Cancer 13:97CrossRefPubMedPubMedCentral
71.
Zhou H, Xu X, Xun Q, Yu D, Ling J, Guo F, Yan Y, Shi J, Hu Y (2012) microRNA-30c negatively regulates endometrial cancer cells by targeting metastasis-associated gene-1. Oncol Rep 27:807–812PubMed
72.
Shang C, Lu Y, Meng L (2012) MicroRNA-125b down-regulation mediates endometrial cancer invasion by targeting ERBB2. Med Sci Monit 18:BR149–BR155CrossRefPubMedPubMedCentral
73.
Zhuang XP, Jin WW, Teng XD, Yuan ZZ, Lin QQ, Xu ST (2015) c-Met and RON expression levels in endometrial adenocarcinoma tissue and their relationship with prognosis. Eur J Gynaecol Oncol 36:255–259PubMed
74.
Dong P, Konno Y, Watari H, Hosaka M, Noguchi M, Sakuragi N (2014) The impact of microRNA-mediated PI3K/AKT signaling on epithelial–mesenchymal transition and cancer stemness in endometrial cancer. J Transl Med 12:231CrossRefPubMedPubMedCentral
75.
Wang Y, Tang Q, Li M, Jiang S, Wang X (2014) MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA. Biochem Biophys Res Commun 444:199–204CrossRefPubMed
76.
Yu Q, Wu H, Huang X, Shen H, Shu Y, Zhang B, Xiang C, Yu S, Guo R, Chen L (2014) MiR-1 targets PIK3CA and inhibits tumorigenic properties of A549 cells. Biomed Pharmacother 68:155–161CrossRefPubMed
77.
Guo C, Sah JF, Beard L, Willson James K V, Markowitz SD, Guda K (2008) The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosom Cancer 47:939–946CrossRefPubMedPubMedCentral
78.
Noguchi S, Yasui Y, Iwasaki J, Kumazaki M, Yamada N, Naito S, Akao Y (2013) Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways. Cancer Lett 328:353–361CrossRefPubMed
79.
Zhao X, Zhu D, Lu C, Yan D, Li L, Chen Z (2016) MicroRNA-126 inhibits the migration and invasion of endometrial cancer cells by targeting insulin receptor substrate 1. Oncol Lett 11:1207–1212PubMed
80.
Dong P, Karaayvaz M, Jia N, Kaneuchi M, Hamada J, Watari H, Sudo S, Ju J, Sakuragi N (2013) Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene 32:3286–3295CrossRefPubMed
81.
Bing L, Hong C, Li-Xin S, Wei G (2014) MicroRNA-543 suppresses endometrial cancer oncogenicity via targeting FAK and TWIST1 expression. Arch Gynecol Obstet 290:533–541CrossRefPubMed
82.
Yamamoto N, Nishikawa R, Chiyomaru T, Goto Y, Fukumoto I, Usui H, Mitsuhashi A, Enokida H, Nakagawa M, Shozu M, Seki N (2015) The tumor-suppressive microRNA-1/133a cluster targets PDE7A and inhibits cancer cell migration and invasion in endometrial cancer. Int J Oncol 47:325–334PubMed
83.
Forget MA, Desrosiers RR, Beliveau R (1999) Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can J Physiol Pharmacol 77:465–480CrossRefPubMed
84.
Yu D, Zhou H, Xun Q, Xu X, Ling J, Hu Y (2012) microRNA-103 regulates the growth and invasion of endometrial cancer cells through the downregulation of tissue inhibitor of metalloproteinase 3. Oncol Lett 3:1221–1226PubMedPubMedCentral
85.
Rak B, Garbicz F, Paskal W, Pelka K, Marczewska JM, Wolosz D, Wlodarski P (2016) The expression of MMP-14 and microRNA-410 in FFPE tissues of human endometrial adenocarcinoma. Histol Histopathol. doi:10.​14670/​HH-11-728 (in press) PubMed
86.
Dai Y, Xia W, Song T, Su X, Li J, Li S, Chen Y, Wang W, Ding H, Liu X, Li H, Zhao Q, Shao N (2013) MicroRNA-200b is overexpressed in endometrial adenocarcinomas and enhances MMP2 activity by downregulating TIMP2 in human endometrial cancer cell line HEC-1A cells. Nucleic Acid Ther 23:29–34CrossRefPubMedPubMedCentral
Metadaten
Titel
The future therapy of endometrial cancer: microRNA’s functionality, capability, and putative clinical application
verfasst von
Matthias B. Stope
Dominique Koensgen
Jörg Weimer
Madeleine Paditz
Martin Burchardt
Dirk Bauerschlag
Alexander Mustea
Publikationsdatum
14.09.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 5/2016
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-016-4194-7

Weitere Artikel der Ausgabe 5/2016

Archives of Gynecology and Obstetrics 5/2016 Zur Ausgabe

General Gynecology

Long-term quality of life, satisfaction, pelvic floor symptoms and regret after colpocleisis

Maternal-Fetal Medicine

Color Doppler examination for the diagnosis of subacute puerperal uterine inversion

Gynecologic Oncology

Long-term experiences with genetic consultation in people with hereditary breast and ovarian cancer

Maternal-Fetal Medicine

Isolated single umbilical artery is an independent risk factor for perinatal mortality and adverse outcomes in term neonates

Gynecologic Oncology

The prognostic value and clinicopathological significance of CD44 expression in ovarian cancer: a meta-analysis

Gynecologic Oncology

Prognostic factors for recurrence in early stage adult granulosa cell tumor of the ovary

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise